Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors.
BACKGROUND
Dysbindin gene (dystrobrevin-binding-protein 1, DTNBP1) variants have been associated with several psychiatric conditions including mood disorders and antidepressant efficacy. We investigated dysbindin gene (DTNBP1) variants in major depression and clinical response to selective serotonin reuptake inhibitors.


METHODS
In this study we investigated the role of DTNBP1 gene (rs3213207, rs2005976, rs760761 and rs2619522) in 313 major depressive outpatients and 149 healthy individuals. One hundred and forty-seven depressive patients were treated with citalopram and evaluated for response (4th week) and remission (12th week) by the 1-item Hamilton Depression Rating Scale. Single nucleotide polymorphisms (SNPs) were assayed by using Applied Biosystems TaqMan technology.


RESULTS
Genotype and haplotype frequencies for four SNPs within DTNBP1 gene did not significantly differ between patients and controls. Allele distribution of SNP rs760761, however, showed a trend of difference between responders and nonresponders (4th week). Haplotype analyses produced a significant association with response to treatment at week 4. No differences were found in remission (12th week).


CONCLUSIONS
DTNBP seems to have an effect on short-term clinical response to citalopram. New studies focused on other genes involved in glutamatergic neurotransmission and related proteins could help to elucidate the complex mechanism of clinical response to antidepressants.
Arias
Bárbara
B
Unitat d'Antropologia (Dep de Biologia Animal) Facultat de Biologia and Institut de Biomedicina, Universitat de Barcelona Barcelona, Spain. barbara.arias@ub.edu
Serretti
Alessandro
A
Mandelli
Laura
L
Gastó
Cristóbal
C
Catalán
Rosa
R
Ronchi
Diana De
DD
Fañanás
Lourdes
L
D002352:Carrier Proteins / Q000235:genetics*; D016022:Case-Control Studies; D015283:Citalopram / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D005260:Female; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
D002352:Carrier Proteins; D015283:Citalopram; D000074765:Dysbindin; D049029:Dystrophin-Associated Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C432416:DTNBP1 protein, human